[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542090":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":104,"collaborators":28,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":108,"sex":114,"minAge":115,"maxAge":28,"enrollmentInfo":116,"targetDuration":28,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":135,"whyStopped":28,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"University Hospital, Grenoble","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Piperacillin Tazobactam","EXPERIMENTAL","75 patients under VA-ECMO receiving a novel administration of Piperacillin Tazobactam.",[13],"Diagnostic Test: Therapeutic drug monitoring of beta-lactam",{"label":15,"type":10,"description":16,"interventionNames":17},"Cefepime","75 patients under VA-ECMO receiving a novel administration of Cefepime.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Meropenem","75 patients under VA-ECMO receiving a novel administration of Meropenem.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DIAGNOSTIC_TEST","Therapeutic drug monitoring of beta-lactam","During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin",[15,19,9],null,[30],{"name":31,"affiliation":5,"role":32},"ALEXANDRE BEHOUCHE, MD","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":28,"email":37},"CONTACT","04 76 76 68 79","ABehouche@chu-grenoble.fr",{"name":39,"role":35,"phone":36,"phoneExt":28,"email":40},"Anaîs ADOLLE","aadolle@chu-grenoble.fr",[42,54,66,78,90],{"facility":43,"status":28,"city":44,"state":28,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":28},"CHU de Clermont Ferrand - Hôpital Gabriel Montpied","Clermont-Ferrand","63003","France","FR",{"type":49,"coordinates":50},"Point",[51,52],3.08682,45.77969,{"lat":52,"lon":51},{"facility":55,"status":28,"city":56,"state":28,"zip":57,"country":46,"countryCode":47,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"CHU Dijon-Bourgogne","Dijon","21000",{"type":49,"coordinates":59},[60,61],5.01391,47.31344,{"lat":61,"lon":60},[64],{"name":65,"role":35,"phone":28,"phoneExt":28,"email":28},"Pierre-Alain BAHR, MD",{"facility":67,"status":28,"city":68,"state":28,"zip":69,"country":46,"countryCode":47,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Aphp Pitie Salpetriere","Paris","75013",{"type":49,"coordinates":71},[72,73],2.3488,48.85341,{"lat":73,"lon":72},[76],{"name":77,"role":35,"phone":28,"phoneExt":28,"email":28},"PAULINE DUREAU, MD",{"facility":79,"status":28,"city":80,"state":28,"zip":81,"country":46,"countryCode":47,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"CHU ROUEN - Hôpital Charles-Nicolle","Rouen","76031",{"type":49,"coordinates":83},[84,85],1.09932,49.44313,{"lat":85,"lon":84},[88],{"name":89,"role":35,"phone":28,"phoneExt":28,"email":28},"Emmanuel BESNIER, MD, PhD",{"facility":91,"status":28,"city":92,"state":28,"zip":93,"country":46,"countryCode":47,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Hôpital Rangueil - CHU Toulouse","Toulouse","31059",{"type":49,"coordinates":95},[96,97],1.44367,43.60426,{"lat":97,"lon":96},[100,102],{"name":101,"role":35,"phone":28,"phoneExt":28,"email":28},"Stéphanie RUIZ, MD",{"name":103,"role":35,"phone":28,"phoneExt":28,"email":28},"Camille MANE, MD",{"type":105,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100542090","pharmacokinetics-and-modelling-of-beta-lactam-in-ecmo-va-patients-100542090",false,"NCT06338345","Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients","Pharmacokinetics and Modelling of Beta-Lactam in Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)","KAMELOT","Inclusion Criteria:\n\n* Patients undergoing VA-ECMO\n* Patients requiering initiation of a novel antibiotic therapy with one of the studied beta-lactam (Piperacillin-Tazobactam, Cefepime, or Meropenem) while under VA-ECMO\n* With an expected survival exceeding 24 hours\n* Patient's or their trusted person's consent\n\nExclusion Criteria:\n\n* Subject under administrative or judicial surveillance\n* Non-affiliation to social insurance\n* Pregnant or lactating patient\n* Antibiotic therapy of interest already initiated before VA-ECMO implantation\n* Contraindication to the use of beta-lactam\n* Administration modalities of beta-lactam not compliant with current recommendations\n* Subject in exclusion period from another study","ALL","18 Years",{"count":117,"type":118},225,"ESTIMATED","INTERVENTIONAL",[121],"NA","The use of antibiotic therapy is common in intensive care units and primarily involves beta-lactams. Its optimal implementation is made difficult by the pharmacokinetic changes inherent in critically ill patients.\n\nDespite the current recommendations from the French Society of Anesthesiology and Intensive Care (SFAR) and the French Society of Pharmacology and Therapeutics (SFPT), there are no recommendations on prescription modalities for patients under veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The use of antibiotic therapy is common in VA-ECMO patients and their pharmacokinetic variability factors are then exacerbated.\n\nWe aim to conduct a prospective, multicenter, interventional study designed to identify predictive factors for failure to achieve therapeutic target circulating concentrations of beta-lactams in patients under VA-ECMO treated with one of the studied beta-lactams",[124,125,126,127,128],"Cardiogenic Shock","Post-cardiac Surgery","Cardiac Arrest","Extracorporeal Membrane Oxygenation Complication","Infections",[130,131,132,133,134],"VA-ECMO","Infection","Beta-lactam","Pharmacokinetic","Modelling","NOT_YET_RECRUITING","2024-03-21",{"date":138,"type":139},"2024-03-29","ACTUAL",{"date":141,"type":118},"2024-09-01",{"date":143,"type":118},"2028-09-01",{"name":5,"class":6},5]